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Anti-pseudomonas aminoglycosides, such as amikacin and tobramycin, are used in the
treatment of Pseudomonas aeruginosa infections. However, their use is linked to the devel-
opment of resistance. During the last decade, the MexXY multidrug efﬂux system has
been comprehensively studied, and numerous reports of laboratory and clinical isolates
have been published. This system has been increasingly recognized as one of the primary
determinants of aminoglycoside resistance in P. aeruginosa. In P. aeruginosa cystic ﬁbrosis
isolates, upregulation of the pump is considered the most common mechanism of amino-
glycoside resistance. Non-fermentative Gram-negative pathogens possessing very close
MexXY orthologs such as Achromobacter xylosoxidans and various Burkholderia species
(e.g., Burkholderia pseudomallei and B. cepacia complexes), but not B. gladioli, are intrin-
sically resistant to aminoglycosides. Here, we summarize the properties (e.g., discovery,
mechanism, gene expression, clinical signiﬁcance) of the P. aeruginosa MexXY pump and
other aminoglycoside efﬂux pumps such as AcrD of Escherichia coli, AmrAB-OprA of B.
pseudomallei, and AdeABC of Acinetobacter baumannii. MexXY inducibility of the PA5471
gene product, which is dependent on ribosome inhibition or oxidative stress, is noteworthy.
Moreover, the discovery of the cognate outer membrane component (OprA) of MexXY in
the multidrug-resistant clinical isolate PA7, serotype O12 deserves special attention.
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INTRODUCTION
Pseudomonas aeruginosa has been recognized as an increasingly
important and worrisome species in health care-associated infec-
tions (Poole, 2011). This bacterium possesses intrinsic resistance
to many antimicrobials because of the low permeability of its
outer membrane barrier and the presence of multidrug efﬂux
transporters (Nikaido, 1994; Hancock, 1998). Although ﬂuo-
roquinolones (e.g., ciproﬂoxacin), broad-spectrum β-lactams
(e.g., imipenem), and anti-pseudomonas aminoglycosides (e.g.,
amikacin) are often available for treatment, P. aeruginosa read-
ily acquires resistance to these anti-pseudomonas agents via
chromosomal mutations and lateral gene transfer (Poole, 2011).
The emergence and spread of multidrug-, extensive drug-, and
pandrug-resistant P. aeruginosa infections is of great concern as
very few agents are effective against these strains (Fischbach and
Walsh, 2009; Poole, 2011). The problem of increasing antimicro-
bial resistance is evenmore threatening when considering the very
limited number of new antimicrobial agents in development (Fis-
chbach and Walsh, 2009). In particular, the prospects of ﬁnding
new antibiotics for Gram-negative pathogens are poor because of
the low permeability of their outer membrane barriers and the
presence of multidrug efﬂux transporters (Fischbach and Walsh,
2009). To combat these bacteria efﬁciently, it is necessary to under-
stand the molecular basis of the efﬂux mechanisms involved in
limiting the intracellular (or periplasmic) concentration of many
antibiotics (Nikaido and Pages, 2012).
The most clinically relevant multidrug efﬂux systems in
Gram-negative bacteria are those of the resistance-nodulation-cell
division (RND) family (Poole, 2004, 2012; Piddock, 2006; Lister
et al., 2009). P. aeruginosa expresses several RND-type mul-
tidrug efﬂux systems, of which MexAB-OprM, MexCD-OprJ,
MexEF-OprN, and MexXY are signiﬁcant determinants of mul-
tidrug resistance in laboratory and clinical isolates (Poole, 2004,
2012; Piddock, 2006; Lister et al., 2009). These pumps are three-
component systems comprising antiporters of the RND family
driven by proton motive force (MexB, MexD, MexF, and MexY),
outer membrane factors (OMF; OprM, OprJ, and OprN), and
periplasmicmembrane fusion proteins (MFP;MexA,MexC,MexF,
and MexX; Piddock, 2006; Lister et al., 2009). These pumps prob-
ably function in a similar manner with AcrAB-TolC, which is
the best-studied RND-type multidrug pump of Escherichia coli
(Nakashima et al., 2011; Nikaido, 2011).
Among them, the MexXY system is intriguing in that it is a
signiﬁcant determinant of aminoglycoside resistance only in P.
aeruginosa, with numerous reports of clinical isolates during the
last decade (Nikaido and Pages, 2012; Poole, 2012). Relatively
few bacterial drug efﬂux systems are known to accommodate
aminoglycosides (Poole, 2012). In addition to MexXY, AmrAB-
OprA of B. pseudomallei is noteworthy for its contribution to this
organism’s intrinsic aminoglycoside resistance, while AdeABC of
Acinetobacter baumannii is implicated in acquired aminoglycoside
resistance (Poole, 2012). The upregulation of the MexXY pump
is considered the most common mechanism of resistance (Arm-
strong andMiller, 2010) and appears to be the major determinant
of aminoglycoside resistance in cystic ﬁbrosis (CF) lung isolates of
P. aeruginosa (Poole, 2011). Here, we summarize the properties
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of these pumps and discuss how to combat efﬂux-mediated
aminoglycoside resistance.
PRE-MexXY DISCOVERY ERA: RND MULTIDRUG EFFLUX
PUMPS AS DETERMINANTS OF RESISTANT TO A
WIDE RANGE OF ANTIMICROBIALS, BUT NOT
AMINOGLYCOSIDES
In 1993, the ﬁrst RND-type multidrug efﬂux system of P. aerug-
inosa, MexAB-OprM (OprM was called OprK at that time), was
discovered at approximately the same time as theAcrAB (AcrBwas
called AcrE at that time) system of E. coli (Poole et al., 1993b). It
was the ﬁrst genetic evidence that an efﬂux operon was involved
in multiple antibiotic resistance in P. aeruginosa (Poole et al.,
1993b). The following year, the efﬂux activity of tetracycline,
chloramphenicol, norﬂoxacin, and benzylpenicillin was shown
using antibiotic accumulation assays in intact cells, which was
the ﬁrst biochemical evidence of the role of efﬂux in intrinsic
multidrug resistance in P. aeruginosa (Li et al., 1994a,b; Li et al.,
1995). Taken together, the MexAB-OprM system was shown to
contribute to the intrinsic resistance of P. aeruginosa to a wide
range of antimicrobial compounds including ﬂuoroquinolones,
tetracycline, chloramphenicol, and β-lactams such as carbenicillin
(Poole et al., 1993b; Li et al., 1995). Its homologs (MexCD-OprJ
and MexEF-OprN) were then discovered as determinants of nfxB
and nfxC ﬂuoroquinolone-resistant (e.g., norﬂoxacin) mutants
from P. aeruginosa (Poole et al., 1996; Kohler et al., 1997). Inci-
dentally, these two pumps are not expressed in normal laboratory
growth conditions, but are induced under some conditions in
wild-type P. aeruginosa (e.g., Morita et al., 2003; Fetar et al., 2011).
An unidentiﬁed efﬂux system that requires OprM was shown to
contribute to resistance to quinolones and cephalosporins, such
as cefpirome, erythromycin, and tetracycline, but not β-lactams,
such as cefoperazone and carbenicillin, in the P. aeruginosa PAO1
background (Zhao et al., 1998). More details on these three pumps
can be found in recent reviews (e.g., Li and Nikaido, 2004, 2009;
Lister et al., 2009).
In those days, RND multidrug efﬂux systems such as MexAB-
OprM and AcrAB-TolC, which can handle a wide variety of
drugs that appear to contain hydrophobic domains of signiﬁ-
cant sizes (Nikaido, 1996), were considered to be similar to the
P-glycoprotein multidrug efﬂux pump of mammalian cells, which
extrudes not only basic compounds but also neutral and weakly
acidic compounds (Nikaido, 1994). However, there was no evi-
dence for the efﬂux of aminoglycosides, which are very hydrophilic
compounds, among the antibiotics used to treat P. aeruginosa
infections (Li et al., 1994a; Nikaido, 1996).
MexXY SYSTEM OF P. aeruginosa WAS IDENTIFIED BY
THREE DIFFERENT GROUPS
The MexXY system was discovered in 1999 in Japan as the fourth
RND-type multidrug efﬂux system of P. aeruginosa PAO1 (Mine
et al., 1999). This systemwas functionally expressed and conferred
resistance to ﬂuoroquinolones, tetracycline, erythromycin, etc. in
theE. coliKAM3mutant (Morita et al., 1998) lacking the acrB gene,
which is an RND transporter component of the major multidrug
efﬂux pump (AcrAB-TolC) inE. coli. Interestingly, unlike the other
three already known systems, no open-reading frame encoding
the outer membrane component, such as OprM, was found in
the region downstream from the mexY gene (Mine et al., 1999).
However, this system was found to function cooperatively with
OprM of P. aeruginosa and TolC of E. coli (Mine et al., 1999).
Nine months after the discovery described above, a French
group showed that MexXY was involved in the natural resistance
of P. aeruginosa PAO1 to aminoglycosides as well as tetracycline
and erythromycin (Aires et al., 1999). Although the overexpression
of MexXY increased the level of resistance to ﬂuoroquinolones in
P. aeruginosa PAO1 cells, disruption of mexXY from PAO1 had
no detectable effect on susceptibility to these agents (Aires et al.,
1999). mexZ, which is located upstream of but transcribed sepa-
rately from mexXY, was identiﬁed (Aires et al., 1999). Its product,
MexZ, contains a helix-turn-helix motif, which is characteristic of
DNA-binding proteins, at its N-terminus, similar to the repres-
sors of RND-type multidrug efﬂux genes (e.g., AcrR, a repressor
of acrAB in E. coli), supporting the notion that mexZ negatively
controls the expression of the operon (Aires et al., 1999).
The following month (10 months after the ﬁrst discovery), a
group in the USA showed that MexXY, which they called AmrAB,
was an aminoglycoside impermeability factor in spontaneous
aminoglycoside-resistant mutants of the impermeability pheno-
type from P. aeruginosa PAO1 (Westbrock-Wadman et al., 1999).
Interestingly, a dramatic decrease in the amount of OprM was
observed in the mutants compared to wild-type PAO1, indicat-
ing that OprM is unlikely to be the outer membrane component
associated with this efﬂux system in the mutants (Westbrock-
Wadman et al., 1999). In addition, MexXY was shown to be
upregulated in clinical P. aeruginosa isolates displaying amino-
glycoside impermeability, suggesting that the pump is a clinically
relevant mechanism of aminoglycoside resistance in P. aeruginosa
(Westbrock-Wadman et al., 1999).
The following year, the complete genomic sequence of P. aerug-
inosa strain PAO1 (PAO1-UW) was published in Nature (Stover
et al., 2000). Although the locus IDs PA2019-18 of the PAO1-UW
genome sequence correspond to the mexXY genes, the nucleotide
sequences of PA2019-18werenot identicalwith those of previously
published mexXY (Aires et al., 1999; Mine et al., 1999) ﬁndings.
This is probably because the DNA sequencing technology at that
time was unable to analyze GC-rich bacteria such as P. aerugi-
nosa (66–67% GC content; Winsor et al., 2011). Therefore, we
analyzed MexXY using the nucleotide sequences from the PAO1-
UW complete genome (Winsor et al., 2011) because we live in the
post-genome era.
STRUCTURE AND FUNCTION OF MexY
The RND components of RND-type tripartite multidrug efﬂux
pumps determine substrate speciﬁcity (e.g., Srikumar et al., 1997;
Eda et al., 2003); therefore, we focused on the structure and func-
tion of MexY rather thanMexX orOprM.Very recently, the crystal
structure of the RND-type multidrug efﬂux pump AcrB of E. coli
revealed the presence of two discrete, high-volumemultisite bind-
ing pockets that contribute to the remarkably broad substrate
recognition of AcrB and its homologs (Nakashima et al., 2011).
Although we basically assume that MexY pumps out antimicro-
bials in a similar manner as AcrB, it will be intriguing to uncover
the molecular basis of howMexY accommodates aminoglycosides
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because they are strongly hydrophilic molecules that are com-
pletely different from the relatively hydrophobic compounds (e.g.,
minocycline, doxorubicin, rifampicin, and erythromycin) used as
substrates of AcrB (Nakashima et al., 2011).
Generally speaking, the function of a transporter (e.g., sub-
strate speciﬁcity and energy coupling) should be determined by
its time course efﬂux assay and evaluated using kinetic con-
stants (e.g., Yerushalmi et al., 1995; Edgar and Bibi, 1997; Mine
et al., 1998; Morita et al., 2000). However, it is difﬁcult to con-
duct such an assessment in a small bacteriology laboratory. The
reconstitution of proteoliposomes revealed that AcrB, AcrD, and
MdtBC of E. coli were H+/drug antiporters (Zgurskaya and
Nikaido, 1999; Aires and Nikaido, 2005; Kim et al., 2010), and
we assume that MexY pumps out antimicrobials coupled with
the same energy. In addition, ﬁve charged and polar amino acid
residues that are involved in the proton translocation pathway
are conserved between MexY and AcrB of E. coli (Takatsuka
and Nikaido, 2006). Unfortunately, the puriﬁcation, reconsti-
tution, and characterization of the MexXY pump remain to be
established, and the energy coupling and substrate speciﬁcity of
MexXY has not been examined through its efﬂux activity. On
the other hand, the MexXY-mediated energy-dependent efﬂux
activity of ethidium (Mine et al., 1999), aminoglycosides (Aires
et al., 1999; Vogne et al., 2004), tetracycline (Aires et al., 1999),
Ala-Nap (MC-005,556) (Mao et al., 2001), and ﬂuorescein-di-β-
D-galactopyranoside (Matsumoto et al., 2011) has been measured
in whole cells.
It is conventional to use differences in minimum inhibitory
concentrations (MICs) between bacterial cells with and without a
multidrug efﬂux transporter to estimate substrate speciﬁcity (e.g.,
Nishino and Yamaguchi, 2001; Nishino et al., 2003). Although
the comparison of MICs can sometimes be a misleading indi-
cator of pump function (e.g., Nagano and Nikaido, 2009), it
can still indicate the possible clinical relevance of a pump (e.g.,
Poole, 2004, 2012; Piddock, 2006). Mutant strains lacking major
multidrug efﬂux pump(s) have been used to determine sub-
strate speciﬁcity (e.g., Nishino and Yamaguchi, 2001; Morita et al.,
2001b). The substrate speciﬁcity ofMexXY-OprMwas determined
using a mutant from PAO1 that overproduced MexXY-OprM,
but not MexAB (and AmpC in the case of β-lactams), and were
compared with a mutant lacking MexXY/MexAB-OprM (and
AmpC in the case of β-lactams; Masuda et al., 2000b). MexXY-
OprM-mediated resistance was then observed for quinolones,
macrolides, tetracyclines, aminoglycosides, chloramphenicol, lin-
comycin, and most β-lactams, but not for novobiocin, polymyxin
B, and some β-lactams (carbenicillin, sulbenicillin, cefsulodin, cef-
tazidime, oxacephem, imipenem, and aztreonam) among a wide
variety of antimicrobial agents (Masuda et al., 2000b). In con-
clusion, MexXY-OprM is a multidrug efﬂux transporter whose
speciﬁcity is extraordinary broad, but different compared with
MexAB-OprM, MexCD-OprJ, MexEF-OprN, and other RND
efﬂux transporters in P. aeruginosa. In addition, MexXY-OprM
was the only pump to mediate aminoglycoside resistance and
was thus considered to recognize aminoglycosides as substrates
(Masuda et al., 2000b).
Basic local alignment search tool (BLAST) analysis showed that
MexY was highly conserved in P. aeruginosa strains: more than
99% (99%) identity (positive) for most strains and 97% (98%)
identity (positive) for PA7 (Morita et al., 2012). Therewas no func-
tional difference between the MexYs of PAO1 and PA7 when they
were expressed in eitherE. coli orP. aeruginosa (Morita et al., 2012).
MexY was more similar [70–73% (83–86%) identity (positive)] to
orthologs of B. pseudomallei and various B. cepacia complexes
than other RND pumps of P. aeruginosa and other Pseudomonas
species (Morita et al., 2012). These Burkholderia species, except for
B.mallei, are intrinsically resistant to aminoglycosides (e.g., Kenny
et al., 1999; Thibault et al., 2004; Vermis et al., 2003; Jassem et al.,
2011). B. gladioli is also known to be involved in human infec-
tions (Segonds et al., 2009); however, no MexY (AmrB) ortholog
exists in B. gladioli BSR3 (Seo et al., 2011), consistent with the
fact that all isolates tested were susceptible to aminoglycosides
(Segonds et al., 2009). Interestingly, the most similar functional
ortholog to MexY exists in Achromobacter xylosoxidans and has
a 74% identity (86% positive); this pump was named AxyY in
strainAXX-A (Bador et al., 2012).A. xylosoxidans is also an oppor-
tunistic human pathogen capable of causing a wide range of
infections (Glupczynski et al., 1988; Bador et al., 2011). Most A.
xylosoxidans clinical isolates were resistant to the tested amino-
glycosides, including amikacin (Ngeow and Puthucheary, 1985;
Glupczynski et al., 1988). The AxyY pump contributes to amino-
glycoside resistance in a similar manner to MexY and AmrBs
(Bador et al., 2012).
COBALT analysis is a multiple sequence alignment tool for
ﬁnding a collection of pairwise constraints. Such constraints are
derived fromdata of the conserveddomaindatabase, proteinmotif
database, and sequence similarity of RND pumps (Papadopou-
los and Agarwala, 2007), including all pumps from P. aeruginosa
PAO1-UW and E. coli K12 (MG1655). The exception is heavy
metal efﬂux pumps, which are characterized by their relation-
ships. Therefore, we focused on the four branches containing the
four Mex pumps in P. aeruginosa (Figure 1). The MexY branch
is located next to the MexD branch and includes the AmrBs
of Burkholderia species (e.g., Mima and Schweizer, 2010) and
AxyY of A. xylosoxidans (Bador et al., 2012). The MexD branch
includes the AdeB pump of A. baumannii (Magnet et al., 2001),
MtrD of Neisseria gonorrhoeae (Hagman et al., 1997), and BdeB of
Bradyrhizobium japonicum (Lindemann et al., 2010). The SmeZ
pump of S. maltophilia, which can mediate aminoglycoside resis-
tance (Crossman et al., 2008), also belongs to the MexD branch.
Many pumps in theMexY/MexD branches canmediate aminogly-
coside resistance (e.g., Magnet et al., 2001; Crossman et al., 2008;
Lindemann et al., 2010;Mima and Schweizer, 2010), which hints at
the structure-function relationship of pumps involved in amino-
glycoside resistance. MexB is located in the branch that contains
the AcrB/D/F andMdtF pumps of E. coli (Nishino andYamaguchi,
2001; Nishino et al., 2003), AdeJ of A. baumannii (Damier-Piolle
et al., 2008), BpeB of B. pseudomallei (Mima and Schweizer, 2010),
AxyB of A. xylosoxidans (Bador et al., 2011), and VmeB of Vib-
rio parahaemolyticus (Matsuo et al., 2007). Among them, some
pumps (e.g., AcrD and MexB) were reported to be involved in
aminoglycoside resistance under some conditions (Li et al., 2003;
Aires and Nikaido, 2005). The MexF branch includes AdeG of A.
baumannii (Coyne et al., 2010) and MdsB of Salmonella enterica
(Nishino et al., 2006).
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FIGURE 1 | Phylogenetic trees for representative RND transporters.
According to the COBALT program, the trees were constructed using the Fast
evolution method and rendered with (A) Rectangle and (B) Radical. Protein
names are abbreviated; for example, “MexY_PAER” stands for “MexY of P.
aeruginosa.” Accession numbers are shown in parentheses. The four
branches shown in red are: (a) MexY, (b) MexD, (c) MexB, and (d) MexF.
Substrate speciﬁcity is determined almost entirely by the
periplasmic domain (i.e., two large extramembrane loops that
largely protrude toward the periplasmic space) of MexY (and
MexB; Eda et al., 2003). MexYF1018L (the F1018L mutation is
located in TMS-12 of MexY base on the structure of AcrB;
Murakami et al., 2002), enhanced the function of MexY, presum-
ably by increasing the efﬂux of aminoglycosides, cefepime, and
ﬂuoroquinolones, which was the ﬁrst example of an improved
efﬂux pump in vivo (Vettoretti et al., 2009b).
GENE EXPRESSION OF THE MexXY SYSTEM
MexXYwas shown to be induced by sub-inhibitory concentrations
of tetracycline, erythromycin, aminoglycosides, tigecycline, and
LMB415 (a peptide deformylase inhibitor), but not oﬂoxacin in
P. aeruginosaPAO1 (Masuda et al., 2000a; Dean et al., 2003; Caugh-
lan et al., 2009). Moreover, oﬂoxacin and cefpirome were also
shown to be inducers, but only in a PAO1 mutant lacking MexAB
(and AmpC in the case of cefpirome; Masuda et al., 2000a,b).
MexZ was shown to bind an inverted repeat region located in
the mexZ-mexX intergenic region directly as a homodimer, which
encompasses the putativemexXY promoter, but the inducers failed
to alter the MexZ-operator interactions (Matsuo et al., 2004). The
crystal structure of MexZ has since been solved (Alguel et al.,
2010). Induction of the MexXY efﬂux pump in P. aeruginosa
PAO1 was shown to be dependent on drug–ribosome interac-
tions (Jeannot et al., 2005), and the pump remained inducible,
but to a lesser degree, by ribosomal inhibitors, even in the mexZ
mutant (Jeannot et al., 2005). These data demonstrate the phys-
iological interactions between MexXY and the ribosome and are
suggestive of an alternative function for MexXY beyond the efﬂux
of antibiotics (Jeannot et al., 2005). Microarray analysis showed
that mexXY were the most highly upregulated genes in P. aerug-
inosa PAO1 after 4 h of interaction with primary normal human
airway epithelial cells (Frisk et al., 2004) and in response to sub-
inhibitory concentrations of tobramycin under normal aerobic
conditions, but not under lethal aerobic conditions or anaerobic
conditions (Kindrachuk et al., 2011).
The antibiotic inducibility of the MexXY multidrug efﬂux sys-
tem of P. aeruginosa was shown to be involved in the modulation
of MexZ activity by the antibiotic-inducible PA5471 gene product
(Morita et al., 2006; Table 1). PA5471 encodes a predicted prod-
uct of 43.5 kDa, which was identiﬁed as a hypothetical protein
conserved between bacteria and archaea, and is a representative of
the uncharacterized protein family UPF0027 in the Pfam protein
families database (Morita et al., 2006) or the PRK09588 cluster
in ProtClustDB (NCBI Protein Clusters Database; Klimke et al.,
2009). Recently, it was demonstrated that RctB of E. coli, which
is related to members of this family, is a novel RNA ligase and
functions as a bona ﬁde RNA repair protein in vivo (Tanaka and
Shuman, 2011). PA5471 is found upstream of and in a possi-
ble operon with an open-reading frame dubbed PA5470; RT-PCR
conﬁrmed both the drug inducibility of PA5470 and its expres-
sion from a polycistronic message that also contains PA5471
(Morita et al., 2006). PA5470 is predicted to encode a peptide
chain release factor of 22.3 kDa (Morita et al., 2006). A homolog
of PA5471 from E. coli K12, ykfJ (b0235), which was, however,
C-terminally truncated (approximately 1 kb; Baranov et al., 2006),
was also shown to be inducible by 4-azaleucine, which is known
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to interfere with translation, and it too is linked to a putative pep-
tide release factor gene (Morita et al., 2006). P. aeruginosa senses
antibiotic-mediated ribosomal disruption and links it to PA5471
gene expression bymonitoring the translation of a 13-amino-acid-
leader peptide region (PA5471.1) found ∼250 bp upstream of the
PA5471 coding sequence on PA5471 mRNA (Morita et al., 2009).
The antimicrobial-inducible PA5471 gene product has been shown
to interact with the repressor MexZ and interfere with its DNA
binding activity in vitro (Yamamoto et al., 2009), and this ﬁnd-
ing contributed to elucidating the molecular mechanisms of the
MexXY induction. However, PA5471 is not sufﬁcient for MexXY
recruitment in response to antibiotic exposure, and additional
antibiotic-dependent effects are needed in P. aeruginosa (Morita
et al., 2009). Exposure to reactive oxygen species (ROS; e.g., per-
oxide) induces the expression of the PA5471 gene, leading to
MexXY-dependent aminoglycoside resistance (Fraud and Poole,
2011). Moreover, long-term (8-day) exposure of P. aeruginosa
to peroxide (mimicking chronic in vivo ROS exposure) increased
the frequency of PA5471- and mexXY -dependent aminoglycoside
resistance (Fraud and Poole, 2011). Recently, reduced (approxi-
mately twofold) expression of the rplU-rpmA operon (encoding
the 50S ribosomal proteins L21 and L27) was shown to promote
mexXY expression via the PA5471 gene in pan-aminoglycoside
resistant mutants from PAO1 and a CF clinical isolate (Lau et al.,
2012). Such expressionwas in the formof ribosomal proteinmuta-
tions that inﬂuence mexXY expression, including rplY (encoding
ribosomal protein L25; El’Garch et al., 2007) and rplA (encoding
ribosomal proteinL1;Westbrock-Wadmanet al.,1999). Transcrip-
tome proﬁling revealed that signiﬁcantly increased expression was
observed for the mexXY and PA5471 genes in both the PA2572
and PA2573 mutants compared with the wild-type PAO1 strain
during exponential growth in Luria–Bertani media (McLaugh-
lin et al., 2012). PA2572 encodes a putative response regulator
of a two-component system required for full virulence to Gal-
leria mellonella (Wax moth) and PA2573 also encodes an ophan
chemotaxis sensor which seems to function in part through signal
transduction involving PA2572 (McLaughlin et al., 2012).
A recent study identiﬁed a gene, parR, encoding the response
regulator of a two-component system, ParRS, which promotes
either induced or constitutive mexXY upregulation, thereby acti-
vating the MexXY efﬂux system as well as OprD porin loss and
lipopolysaccharide modiﬁcation in a MexZ-independent manner
(Muller et al., 2011). Overexpression of PaeIII, a small non-coding
RNA between PA3505 and PA3536 in the genome of P. aerugi-
nosa PAO1, in the stationary phase increased the expression of
the mexXY and mexZ genes as well as type III secretion genes,
while reducing the expression of genes for arginine metabolism
(Goldberg et al., 2008).
MexXY SYSTEM AS AN ANTIMICROBIAL RESISTANCE
DETERMINANT IN P. aeruginosa
Pseudomonas aeruginosa shows intrinsic resistance against many
antimicrobials because of the low permeability of its outer mem-
brane and the presence of efﬂux systems (Nikaido, 1994; Hancock,
1998). MexXY was shown to be involved in natural resistance
to aminoglycosides, tetracycline, tigecycline, erythromycin, and
LBM415 in P. aeruginosa PAO1 (Aires et al., 1999; Masuda et al.,
2000a; Morita et al., 2001a; Dean et al., 2003; Caughlan et al.,
2009). MexXY was also shown to be necessary for the adaptive
resistance of P. aeruginosa PAO1 to aminoglycosides (Hocquet
et al., 2003). It is of note that MexXY is the only pump of the 12
identiﬁedRNDsystems thatmediates aminoglycoside resistance in
P. aeruginosa PAO1 (Poole, 2011). The antagonism of aminoglyco-
sides by the divalent cations Mg2+ and Ca2+ is well documented
(Medeiros et al., 1971), and culture in cation-adjusted Mueller–
Hinton broth is recommended as a susceptibility test to ensure
acceptable results when P. aeruginosa isolates are tested (Barry
et al., 1992). MexXY was shown to be required for the antagonism
of aminoglycosides by divalent cations inP. aeruginosa PAO1 (Mao
et al., 2001). Although Phe-Arg-β-naphthylamide (PAβN, MC-
207,110) is known as a non-speciﬁc inhibitor against RND-type
multidrug efﬂux pumps (Lomovskaya et al., 2001), this inhibitor,
as observed for divalent cations, antagonized the activity of amino-
glycosides (amikacin and netilmicin) in a MexXY-dependent
manner, even though it also inhibited MexXY-dependent ﬂuoro-
quinolone (levoﬂoxacin) resistance (Mao et al., 2001). Conversely,
PAβN inhibited MexXY-mediated aminoglycoside (gentamicin)
resistance (Mesaros et al., 2007). The reason for the discrepancy
between these two results remains unknown. Increased suscep-
tibility to aminoglycosides in nfxB mutants, which upregulate
mexCD-oprJ expression, was correlated with increased resistance
to ﬂuoroquinolones and some β-lactams, such as cefepime, con-
comitant with a higher susceptibility to aminoglycosides and some
β-lactams, such as ticarcillin, aztreonam, and imipenem. This was
shown to be partly due to the impaired activity of MexXY-OprM
because of major changes in cell physiology, but not the expres-
sion/production of mexY /MexY and oprM/OprM (Jeannot et al.,
2008; Mulet et al., 2011). The increased susceptibility to amino-
glycosides inMexEF-OprN-overproducing nfxC mutants was also
observed, apparently owing to impairment of the MexXY system
(Sobel et al., 2005). mexXY expression (and so MexXY-mediated
resistance)was independent of theAmgRS two-component system
in whichmutations enhanced aminoglycoside action to control an
adaptive response to membrane stress (Lee et al., 2009).
Multidrug resistant P. aeruginosa clinical isolates have often
been reported to beMexXY overproducers (e.g., Llanes et al., 2004,
2006; Wolter et al., 2004; Deplano et al., 2005; Henrichfreise et al.,
2007; Hocquet et al., 2007; Maniati et al., 2007; Vettoretti et al.,
2009a; Beaudoin et al., 2010; Xavier et al., 2010; Fehlberg et al.,
2012; Pasca et al., 2012). Time series analysis (January 1999 to
January 2005) revealed a signiﬁcant relationship between antibi-
otic use (aminoglycosides, ﬂuoroquinolones, and cefepime, but
not carbapenems) and the incidence of MexXY-overproducing P.
aeruginosa in a French hospital (Hocquet et al., 2008). MexXY
(n = 39) and MexAB (n = 31) were the most frequently overpro-
duced pumps in 85 non-CF P. aeruginosa strains with low-level
ciproﬂoxacin resistance (MICs ranging from 0.25 to 2 μg/mL,
which are still susceptible or intermediate according to the CLSI
breakpoints; Llanes et al., 2011). A large proportion of the strains
were MexXY overproducers in genotypically distinct P. aeruginosa
clinical isolates that were less susceptible to cefepime than to cef-
tazidime, and thesewere identiﬁed in Europe (Hocquet et al., 2006;
Pena et al., 2009; CampoEsquisabel et al., 2011) and theUSA (Lao-
havaleeson et al., 2008). In contrast, both cefepime and ceftazidime
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are potent β-lactam antibiotics with similarMICs (1–2μg/mL) for
wild-type P. aeruginosa strains. Moreover, ceftobiprole, similar to
cefepime, selectedMexXY overproducers in clinical studies (Baum
et al., 2009). Actually, a single step MexXY overproducer was
selected in vitro by cefepime and ceftobiprole, but not ceftazidime
(Queenan et al., 2010). MexXY contributed very signiﬁcantly to
the development of high-level (100–1000 μg/mLMIC) aminogly-
coside resistance via a combination of aminoglycoside-modifying
enzymes (AMEs) in multidrug resistant P. aeruginosa non-CF
clinical isolates (Morita et al., 2012). However, AMEs are com-
mon determinants of aminoglycoside resistance in P. aeruginosa,
except for CF isolates (Poole, 2011). In clinical CF isolates,MexXY
has been primarily implicated in pan-aminoglycoside resistance
(e.g., Sobel et al., 2003; Vogne et al., 2004; Islam et al., 2004, 2009).
MexXY was also shown to be necessary in subpopulations of P.
aeruginosa CF isolates that are hypersensitive to ticarcillin (called
Tichs; Vettoretti et al., 2009b). mexZ was shown to be one of
the most frequently mutated genes during chronic infection by
P. aeruginosa in CF patients (Smith et al., 2006; Feliziani et al.,
2010). However, a number of studies highlighted the absence of
mutations in mexZ or the mexXY promoter region in MexXY-
overproducing P. aeruginosa CF isolates (Sobel et al., 2003; Vogne
et al., 2004; Islam et al., 2009). To date, three kinds of mutants
(agrZ, agrW1, and agrW2) have been recognized as MexXY
overproducers as a result of genetic mechanisms: mutants with
impaired binding or unbinding of MexZ due to alterations in the
mexZ or mexZ-mexX intergenic region (type agrZ); mutants with
impaired protein synthesis (type agrW1); and mutants with alter-
ations in parRS (type agrW2; de Bentzmann and Plesiat, 2011).
Oxidative stress, a component of the host’s immune system in the
CF lung, induced mexXY expression via PA5471 and promoted
aminoglycoside resistance (Fraud and Poole, 2011). Under condi-
tions of oxidative stress, P. aeruginosa can develop aminoglycoside
resistance, even in the absence of aminoglycosides (Poole, 2012).
It is also very plausible that the routine use of aminoglycosides
(e.g., tobramycin) might simply select for MexXY-overproducing
P. aeruginosa in the CF lung (Smith et al., 2006).
Although it is obvious that MexXY is one of the determinants
of antimicrobial resistance in P. aeruginosa in the clinical set-
ting (Poole, 2011), only a few reports have assessed the in vivo
impact of theMexXY systemonantibiotic therapy forP. aeruginosa
infections (e.g., Martha et al., 2006).
COGNATE OUTER-MEMBRANE COMPONENT OprA OF THE
MexXY PUMP IS FOUND IN SEROTYPE O12 BUT IS LOST
IN OTHERS
The mexXY operon lacks a gene coding for the outer mem-
brane protein in P. aeruginosa PAO1 (Mine et al., 1999). OprM
is necessary for the function of MexXY and MexAB in P. aerugi-
nosa PAO1 (Aires et al., 1999; Masuda et al., 2000a; Morita et al.,
2001a), although overproduced OpmB (PA2525) can function as
an outer membrane component of MexXY, MexAB, and MexCD
(Murata et al., 2002). Intriguingly, the multidrug resistant taxo-
nomic outlier P. aeruginosa PA7 possesses a unique gene (oprA)
downstream of mexXY encoding an outer membrane channel
that is absent in most P. aeruginosa strains (Roy et al., 2010).
MexXY in this strain utilizes either the OprA or OprM outer
membrane channel (Morita et al., 2012; Table 1). While OprM
is functional with both MexXY and MexAB, OprA did not asso-
ciate as strongly with MexAB as it did with MexXY (Morita
et al., 2012). We compared the OprA of P. aeruginosa PA7 with
the OprM family (Remans et al., 2010) from P. aeruginosa PAO1
as well as TolC of E. coli K12 (Mine et al., 1999), OprA of B.
pseudomallei 1026b (Mima and Schweizer, 2010), OprZ of A.
xylosoxidans AXX-A (Bador et al., 2012), and AdeC of A. bau-
mannii AYE (Magnet et al., 2001; Figure 2). COBALT analysis
showed that OprA of P. aeruginosa PA7 and its close orthologs
(OprA of B. pseudomallei 1026b and OprZ of A. xylosoxidans
AXX-A) is located close to OprJ and is followed by OprM
of the OprM outer membrane family of P. aeruginosa PAO1
(Figure 2).
Interestingly, a small portion of the oprA gene immediately
downstream of the mexY gene in PAO1 was identiﬁed, suggest-
ing that non-PA7 P. aeruginosa strains might have possessed, but
lost, the intactmexXY-oprA efﬂux pump locus (Morita et al., 2012;
Table 1). Consistent with this, the majority of a panel of serotype
strains possessed the truncated oprA, but the serotype O12 iso-
late had an intact mexXY-oprA locus, similar to PA7 and the
related strain DSM 1128 (Morita et al., 2012). O12 is a predom-
inant serotype associated with multidrug resistance to a number
of antibiotic classes, including aminoglycosides and β-lactams,
although it represents aminor serotype in the environment (Pirnay
et al., 2009; Roy et al., 2010). O12might bemore dominant due, in
part, to the presence of oprA in hospitals in which antimicrobials
promoting MexXY-OprA-mediated multidrug resistance, such as
aminoglycosides,were used. P. aeruginosa PA7 isolated before 1984
from a wound infection in Buenos Aires, Argentina (Pirnay et al.,
2009; Roy et al., 2010), might also have acquired multidrug resis-
tance via the heavy use of antibiotics, including gentamicin or
tobramycin, to treat wounds at that time. Apparently, a slightly
increased resistance (two- to fourfold) to amikacin, ciproﬂoxacin,
and cefpirome was shown in the presence and absence of oprA
(Morita et al., 2012). Such a small difference might be signiﬁcant
during antibiotic treatment or in the presence of sub-inhibitory
concentrations of antibiotics.
AcrD IS AN AMINOGLYCOSIDE EFFLUX PUMP THAT IS THE
MOST SIMILAR TO MexY AMONG THE RND PUMPS IN
E. coli K12
AcrD has the highest similarity score at the amino acid level to
MexY of the E. coli K12 RND pumps and was shown to be an
aminoglycoside efﬂux pump as judged byMIC determination and
the aminoglycoside efﬂux assay (Rosenberg et al., 2000). How-
ever, differences in aminoglycoside resistance (uptake) between
the parent strain JC7623 and its acrD-deletion mutant JZM320
was possibly not limited to AcrD function because JZM320 was
constructed by inserting the tet gene from pBR322 into acrD
(Rosenberg et al., 2000). The increased aminoglycoside uptake
might be due to not only AcrD deﬁciency but also to the produc-
tion of an aberrant cytoplasmicmembrane protein (the product of
acrD with the inserted tet) and/or the tetracycline/H+ antiporter
itself (Merlin et al., 1989a,b; Wyka and St John, 1990). While dis-
ruption of tolC or acrA did not increase the susceptibility of K12
to aminoglycosides (Rosenberg et al., 2000), both of them were
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FIGURE 2 | Phylogenetic trees for representative OMPs. According to the COBALT program, the trees were constructed using the Fast evolution method
and rendered with (A) Rectangle and (B) Radical. Protein names are abbreviated; for example, “OprA_PAER” stands for “OprA of P. aeruginosa.” Accession
numbers are shown in parentheses.
necessary for the function of acrD against various antimicrobials;
however, no aminoglycosides were used in the study (Hirakawa
et al., 2003). We do not rule out the hypothesis of Rosenberg
et al. (2000) that AcrD protein can perhaps function without the
participation of AcrA and TolC in the case of aminoglycoside
efﬂux.
It is evident that puriﬁed AcrD can function as an H+-driven
aminoglycoside efﬂux pump(Aires and Nikaido, 2005). Especially,
strong stimulation of proton efﬂux was observed when amino-
glycosides (e.g., streptomycin) were added to the more acidic
intra-vesicular space of reconstituted AcrD proteoliposomes con-
taining AcrA and Mg2+(Aires and Nikaido, 2005), indicating that
AcrD captures aminoglycosides exclusively from the periplasm in
E. coli (Nikaido, 2011). The difference in the MICs of amikacin
and gentamicin between a parent strain and its in-frame acrD-
deletion mutant or between an acrBD-deletion mutant and its
acrD-overexpressing complementationmutantwas approximately
twofold (Elkins and Nikaido, 2002; Aires and Nikaido, 2005).
There was no signiﬁcant difference in kanamycin resistance in
the case of an in-frame deletion (Hirakawa et al., 2003), and
a twofold difference was observed in the case of overproduc-
tion (Nishino and Yamaguchi, 2001; Nishino et al., 2010). An
acrA in-frame deletion mutant also showed an approximately
twofold increased susceptibility to aminoglycosides (Aires and
Nikaido, 2005). However, similar observations were not seen for
AcrB (Nishino and Yamaguchi, 2001; Elkins and Nikaido, 2002;
Aires and Nikaido, 2005). A comparison of the entrances of the
vestibules, which are found in the central cavities (Murakami
et al., 2002) of AcrD (which transports aminoglycosides) and
AcrB (which does not) crystal structures, shows that this area
in AcrD is in line with many more acidic residues that may
attract polycationic substrates (Yu et al., 2003). Treatment with
sub-inhibitory concentrations of kanamycin induced adaptive
resistance to aminoglycosides, which was dependent on acrD
(Sidhu et al., 2012). Aminoglycosides are very hydrophilic and
polycationic and assumingly permeate through the porin chan-
nel in E. coli, unlike P. aeruginosa (Nikaido and Pages, 2012)
in addition to so called “self-promoted” aminoglycoside uptake
across the outer membrane of both of E. coli and P. aeruginosa
(Hancock et al., 1991; Hancock, 1998). The MICs of aminogly-
cosides on E. coli, unlike P. aeruginosa, might be poor indicators
of aminoglycoside efﬂux. There are numerous AcrD homologs
in other Enterobacteriaceae (Poole, 2004). Although the AcrD
of S. enterica serovar Typhimurium ATCC 14028s was studied
comprehensively, no signiﬁcant difference between the AcrDs of
E. coli and S. enterica has been observed so far (Nishino et al.,
2009; Horiyama et al., 2011; Yamasaki et al., 2011). Interest-
ingly, AcrD pumps mediate resistance to the substrates of MexAB
(e.g., carbenicillin, aztreonam, and novobiocin). However, AcrD
pumps did not mediate resistance to the substrates of MexXY
(e.g., cefpirome, erythromycin, and tetraphenylphosphonium)
or shared substrates of both MexAB and MexXY (e.g., ﬂuoro-
quinolone and tetracycline) when differences of the MICs were
compared between a parent strain and its transformant overpro-
ducing the pump (Srikumar et al., 1997; Mine et al., 1999; Morita
et al., 2001a; Nishino et al., 2003, 2009; Horiyama et al., 2011;
Yamasaki et al., 2011).MexAB-OprMwas also shown to contribute
to aminoglycoside resistance, presumably via active efﬂux in the
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low-ionic-strength medium used in this particular study (Li et al.,
2003). AcrD and theMdtABC pumpwere iron-regulated, induced
in low-iron conditions, and export the siderophore enterobactin
(Bochner et al., 2008), which reminds us that MexAB-OprM was
inducible under conditions of iron limitation and compensated
for a growth defect in an iron-deﬁcient medium in the pres-
ence of the non-metabolizable iron chelator 2,2′-dipyridyl (Poole
et al., 1993a,b). AcrD seems to be a functional homolog of MexB
rather than MexY, as determined from substrate speciﬁcity and
physiological function, consistent with the fact that phyloge-
netic analysis showed that AcrD is closer to MexB than to MexY
(Figure 1).
AmrAB-OprA IS A MULTIDRUG EFFLUX SYSTEM THAT
MEDIATES AMINOGLYCOSIDE RESISTANCE IN
B. pseudomallei
Burkholderia pseudomallei is the etiologic agent of melioido-
sis, a rare but serious disease endemic to South Asia, Northern
Australia, and other parts of the tropics (Mima and Schweizer,
2010). Melioidosis is very difﬁcult to treat because of the intrinsic
resistance to many antimicrobial agents including aminoglyco-
sides, macrolides, polymyxins, and some β-lactams (Mima and
Schweizer, 2010). AmrAB-OprA was identiﬁed as an efﬂux deter-
minant of resistance to aminoglycosides and macrolides in the
B. pseudomallei 1026b clinical isolate (Moore et al., 1999). This
pump was actually the ﬁrst to be demonstrated responsible
for the aminoglycoside resistance of RND pumps in Gram-
negative bacteria. The gene product of amrR, which is located
immediately upstream and divergently transcribed from amrAB-
oprA in B. pseudomallei 1026b (Moore et al., 1999), showed
strong homology [60% (73%) identity (positive)] to MexZ,
which acts as a transcriptional repressor of the mexXY operon
of P. aeruginosa PAO1 (Matsuo et al., 2004; Alguel et al., 2010;
Table 1).
While the majority of B. pseudomallei clinical isolates exhibit
high levels of aminoglycoside and macrolide resistance, rare iso-
lates are susceptible to these antibiotics (Simpson et al., 1999;
Trunck et al., 2009). While it is noted that the resistance pro-
ﬁle of those isolates matches that of the amrAB-oprA mutants
(Simpson et al., 1999), it was shown experimentally that amrAB-
oprAwasmissing in B. pseudomallei 708a, an aminoglycoside- and
macrolide-susceptible clinical isolate, and this loss was associated
with the deletion of >130 kb of genetic material (Trunck et al.,
2009). The expression of amrAB-oprA increased resistance to not
only aminoglycosides and macrolides but also ﬂuoroquinolones
and tetracyclines in a BpeAB-OprA pump-deﬁcient mutant of
1026b (Mima and Schweizer, 2010). Judging from the substrate
speciﬁcity and sequence similarity (Mima and Schweizer, 2010),
we have no doubt that AmrAB is a functional ortholog of MexXY
in B. pseudomallei. BpeAB-OprB of B. pseudomallei also report-
edly mediates aminoglycoside resistance in strain KHW (Chan
et al., 2004), while this pump did not confer aminoglycoside resis-
tance in 1026b (Mima and Schweizer, 2010). In addition, the BpeB
RND transporter was also shown to be closely related to MexB
of P. aeruginosa, both functionally and phylogenetically (Mima
and Schweizer, 2010), consistent with our phylogenetic analysis
(Figure 1).
Table 1 | Genetic organization of aminoglycoside efflux operons of
































The genetic organization of genes involved in aminoglycoside efﬂux and their
regulation of expression is summarized. No obvious signiﬁcant differences on
substrate speciﬁcities were observed among the pumps. TetR-type negative
regulators are encoded by genes located upstream of the operons in P. aerugi-
nosa, A. xylosoxydans, and B. pseudomallei, while the AdeRS two-component
regulatory proteins are encoded by genes located upstream of the adeAB
(-adeC) operon.
aoprA gene found in the multidrug-resistant clinical isolate PA7 and relatives, all
of which are serotype O12, is absent and often OprM encoded by the mexAB-
oprM multidrug efﬂux operon is associated with the MexXY component in most
P. aeruginosa strains (Morita et al., 2012). MexXY can utilize OprA or OprM as an
outer membrane channel (Morita et al., 2012).
bAdeC is not essential for AdeAB-mediated resistance (Marchand et al., 2004),
suggesting that AdeAB recruits another yet unknown outer membrane protein
as indicated by the question mark.
cThe question mark signiﬁes other unknown regulatory mechanism(s) involved
in adeABC overexpression (Sun et al., 2010).
As described above, AmrB orthologs are conserved among var-
ious human pathogens belonging to Burkholderia species, but not
B. gladioli. Actually, an AmrAB-OprA ortholog was shown to be a
major aminoglycoside resistance contributor in B. cenocepacia, a
member of the B. cepacia complex (Hamad et al., 2010).
AdeABC IS A MULTIDRUG EFFLUX SYSTEM THAT MEDIATES
AMINOGLYCOSIDE RESISTANCE IN A. baumannii
Acinetobacter baumannii is the most frequently implicated species
in nosocomial infections among Acinetobacter spp. (Coyne et al.,
2011). AdeABC was identiﬁed as an RND-type efﬂux pump
involved in resistance tomultiple antimicrobials including amino-
glycosides, ﬂuoroquinolones, tetracycline, erythromycin, cefo-
taxime, trimethoprim, and chloramphenicol in A. baumannii
BM4454, a low-level pan-aminoglycoside resistant clinical isolate
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(Magnet et al., 2001). The polycistronic adeABC transcript was
conﬁrmed experimentally to encode AdeA (MFP), AdeB (RND
transporter), and AdeC (OMF; Magnet et al., 2001; Marchand
et al., 2004). Because the substrate speciﬁcity of AdeAB is very
similar to that of MexXY, we have no doubt that AdeAB is a func-
tional homolog of MexXY in A. baumannii. AdeC is not essential
for AdeAB-mediated resistance (Marchand et al., 2004), indicating
that AdeAB recruits another outer membrane protein to form a
functional tripartite complex, as observed for the MexXY pump
with OprM in P. aeruginosa (Aires et al., 1999; Mine et al., 1999).
We do not rule out the possibility that AdeAB is functional with
AdeC, as observed for the MexXY pump with its linked outer-
membrane channel OprA, which was not essential in P. aeruginosa
PA7 (Morita et al., 2012). The adeAB genes are usually present, but
the adeC gene was not found in ∼40% of clinical isolates (Nemec
et al., 2007). Our phylogenetic analysis showed that AdeC is more
closely related to OprM andOprJ than to OprA in the OprM outer
membrane family of P. aeruginosa (Figure 2).
The adeABC operon is expressed at low levels in natu-
ral isolates of A. baumannii due to stringent control by the
AdeRS two-component system, which is encoded adjacent to ade-
ABC, but transcribed in the opposite direction (Marchand et al.,
2004; Table 1). Mutations (e.g., AdeRPro116Leu, AdeSThr153Met, or
AdeSGly30Asp) in AdeRS have been shown to be responsible for the
constitutive expression of AdeABC (Marchand et al., 2004), which
reminds us that mutations (e.g., ParRMet59Ile) in the ParRS two-
component system are responsible for the constitutive expression
of MexXY in P. aeruginosa (Muller et al., 2011). Overexpression of
the AdeABC system in a tigecycline non-susceptible clinical iso-
late was due to the transposition of a copy of ISAba1 into adeS
(Ruzin et al., 2007). Very recently, a truncated AdeS kinase protein
generated by an ISAba1 insertion was shown to be correlated with
enhanced adeABC expression in A. baumannii (Sun et al., 2012).
Other regulatory mechanism(s) were shown to be involved in ade-
ABC overexpressionwithout any previously knownmutation (Sun
et al., 2010). Recently theAdeABCorthologwas shown to be a con-
tributor to multiple antimicrobials, including aminoglycosides, in
Acinetobacter genomospecies 13TU, a non-A. baumannii species
(Roca et al., 2011).
FUTURE PERSPECTIVES
MexXY is one of the potential targets for novel anti-pseudomonas
agents. Its inhibitor is able to not only potentiate previously used
ineffective antimicrobial agents (e.g., aminoglycosides against
aminoglycoside-resistant P. aeruginosa and B. cepacia complex),
but also to speed up the development of novel anti-pseudomonas
agents. Because there are a signiﬁcant number of potential drug
targets encoded by the genome of P. aeruginosa (e.g., products
of essential genes; Morita et al., 2010), it is the most promis-
ing therapeutic strategy to conquer the impermeability barriers
of these bacteria. The efﬂux inhibitor MP 601384, which has
speciﬁcity toward aminoglycoside-accommodating RND efﬂux
systems and is not toxic to bacteria, is the only MexXY inhibitor
reported so far (Jassemet al.,2011). Unculturedbacteria andplants
are predicted to be a signiﬁcant reservoir of novel antimicrobial
agents (Stavri et al., 2007; Piel, 2011). Screening novel antibacte-
rial agents, including a MexXY inhibitor, is currently in progress
in our laboratory (e.g., Shiota et al., 2004).
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